In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ACNAP Silver Members, Fellows of the ESC and Young combined Members

Advancing the management of type 2 diabetes through an integrated community based cardiovascular disease prevention programme

Session Oral abstract session: PPCI , risk factors and prevention

Speaker Irene Gibson

Congress : EuroHeartCare 2018

  • Topic : preventive cardiology
  • Sub-topic : Risk Factors and Prevention - Other
  • Session type : Abstract Session
  • FP Number : 239

Authors : I Gibson (Galway,IE), J Jones (London,GB), J Crowley (Galway,IE), D Dunne (Galway,IE), S Connolly (London,GB), G Flaherty (Galway,IE)

I Gibson1 , J Jones2 , J Crowley3 , D Dunne4 , S Connolly5 , G Flaherty6 , 1National Institute of Preventive Cardiology - Galway - Ireland , 2Brunel University - London - United Kingdom , 3Galway University Hospital - Galway - Ireland , 4Croí, West of Ireland Cardiology Foundation - Galway - Ireland , 5Imperial College Healthcare NHS Trust - London - United Kingdom , 6National University of Ireland - Galway - Ireland ,

European Journal of Cardiovascular Nursing ( 2017 ) 17 ( Supplement ), S67

Background:With the prevalence of Type 2 diabetes increasing globally it is imperative that we explore models of care that seek to improve diabetes outcomes in accordance with the recommended total CVD risk approach to prevention.
Purpose: This study examines the effectiveness of a community-based CVD prevention programme on medical and lifestyle risk factor management in a cohort of patients with Type 2 diabetes.
Methods: Patients with Type 2 diabetes were invited to attend a 16- week programme consisting of a professional multi-disciplinary (nurse, dietician, physical activity specialist) lifestyle intervention, with appropriate risk factor and therapeutic management in a community setting. Risk factors such as blood pressure, lipids, smoking, blood glucose, BMI (body mass index), waist circumference and physical activity levels were assessed at baseline, end of programme and at 1 year.
Results: Data on patients who attended Initial Assessment (IA), End of Programme Assessment (EOP) and a 1-Year follow-up (1-yr) were analysed (Table 1.)
Conclusions: Data from this ongoing lifestyle intervention programme suggests that the management of diabetes and cardiovascular disease can be successfully integrated. In addition, this model of care can improve diabetes outcomes with improvements in biomedical, anthropometric and lifestyle risk factors not only being observed at EOP but being sustained at 1-yr.

Patients IA (n=164) Patients EOP (n=164) Patients IA(n=107) Patients 1-yr(n=107)
Mean BMI 35.7 34.6(p<0.001) 35.9 34.8 (p<0.001)
Mean Mediterranean Diet Score (max 14) 4.1 7.2 (p<0.001) 4.0 8.0 (p<0.001)
% Achieving physical activity targets 9.2 56.6 (p<0.001) 12.6 8.0 (p<0.001)
% Smoking 15.3 10.4 (p=0.008) 15.9 13.1 (p=0.45)
% Blood Pressure to target (<140/85mmHg) 44.4 71.9 (p<0.001) 44.3 74.5 (p<0.001)
% LDL to target (<2.6mmol/l) 54.8 80.3 (p<0.001) 52.9 81.7 (p<0.001)
% HbA1c to target (<7%) 53 75 (p<0.001) 54.1 82.4 (p<0.001)
Mean FBG (mmol/l) 7.55 6.69 (p<0.001) 7.41 6.75 (p=0.003)
BMI(Body Mass Index), LDL (Low-Density Lipoprotein), FBG (Fasting Blood Sugar)

The free consultation period for this content is over.

It is now only available year-round to ACNAP Silver Members, Fellows of the ESC and Young combined Members

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are